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Cyclin D1, Id1 and EMT in breast cancer
Nicholas P Tobin1,2, Andrew H Sims3, Katja L Lundgren1, Sophie Lehn1,4 and Göran Landberg1,4*
Abstract
Background: Cyclin D1 is a well-characterised cell cycle regulator with established oncogenic capabilities. Despite
these properties, studies report contrasting links to tumour aggressiveness. It has previously been shown that
silencing cyclin D1 increases the migratory capacity of MDA-MB-231 breast cancer cells with concomitant increase
in ‘inhibitor of differentiation 1’ (ID1) gene expression. Id1 is known to be associated with more invasive features of
cancer and with the epithelial-mesenchymal transition (EMT). Here, we sought to determine if the increase in cell
motility following cyclin D1 silencing was mediated by Id1 and enhanced EMT-features. To further substantiate
these findings we aimed to delineate the link between CCND1, ID1 and EMT, as well as clinical properties in
primary breast cancer.
Methods: Protein and gene expression of ID1, CCND1 and EMT markers were determined in MDA-MB-231 and
ZR75 cells by western blot and qPCR. Cell migration and promoter occupancy were monitored by transwell and
ChIP assays, respectively. Gene expression was analysed from publicly available datasets.
Results: The increase in cell migration following cyclin D1 silencing in MDA-MB-231 cells was abolished by Id1
siRNA treatment and we observed cyclin D1 occupancy of the Id1 promoter region. Moreover, ID1 and SNAI2 gene
expression was increased following cyclin D1 knock-down, an effect reversed with Id1 siRNA treatment. Similar
migratory and SNAI2 increases were noted for the ER-positive ZR75-1 cell line, but in an Id1-independent manner.
In a meta-analysis of 1107 breast cancer samples, CCND1low/ID1high tumours displayed increased expression of EMT
markers and were associated with reduced recurrence free survival. Finally, a greater percentage of CCND1low/
ID1high tumours were found in the EMT-like ‘claudin-low’ subtype of breast cancer than in other subtypes.
Conclusions: These results indicate that increased migration of MDA-MB-231 cells following cyclin D1 silencing
can be mediated by Id1 and is linked to an increase in EMT markers. Moreover, we have confirmed a relationship
between cyclin D1, Id1 and EMT in primary breast cancer, supporting our in vitro findings that low cyclin D1
expression can be linked to aggressive features in subgroups of breast cancer.
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Background
Cyclin D1 along with its binding partners CDK 4/6 par-
tially mediate G1 to S-phase transition of the cell cycle
through phosphorylation and inactivation of retinoblas-
toma (Rb) protein with subsequent release of E2F tran-
scription factors [1-3]. The oncogenic activities of the
protein have been addressed in numerous studies, [4-7]
and many human cancers including breast, colon, and
prostate, overexpress cyclin D1 [8-10]. More recently, a
number of cyclin D1 studies in breast cancer have
focused on functions that are not directly related to cell
cycle maintenance. Cyclin D1 can modulate the activity
of transcription factors and histone deacetylase [11], it
can activate oestrogen receptor in the absence of oestro-
gen [12], and it can bind to the upstream regulatory
region of the diverse Notch1 gene [13]. Previous work
by our group revealed a novel induction of breast cancer
cell migration after cyclin D1 silencing, which may
account for a worse clinical outcome for patients with
low expression of the protein [14]. Of the genes upregu-
lated following this silencing, Inhibitor of differentiation
1 (Id1), a basic helix-loop helix (bHLH) family member,
represents a potential candidate modulating the effect of
cyclin D1 on cell migration.
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The four Id proteins (termed 1-4) represent the class
V subgroup of the bHLH family, however in contrast to
other bHLH transcription factors (that modulate gene
expression though dimerization and DNA binding of
canonical E-box promoter regions in target genes [15]),
the Id proteins lack a DNA binding domain and instead
bind to other bHLH family monomers, negatively regu-
lating their activity [16]. Id1 has been associated with
breast cancer progression in a number of studies. ID1
promoter regulation is lost in aggressive breast cancer
cells [17], Id1 is associated with induction of cell prolif-
eration and invasion [18], and stable antisense targeting
of Id1 represses an aggressive and metastatic phenotype
in mammary epithelial cells [19]. Recent data has also
revealed that cyclin D1 binds to the ID1 promoter
region in the mammary gland, and negatively regulates
its transcription in mouse retina [13]. Given the role of
Id1 in cell invasion and metastasis, it represents a strong
candidate for driving breast cancer cell migration fol-
lowing cyclin D1 silencing.
Increased motility and invasiveness are inherent prop-
erties of a mesenchymal phenotype [20], and the process
whereby a non-motile epithelial cell procures these traits
is termed epithelial to mesenchymal transition (EMT).
Recently, a role for EMT in the process of cancer metas-
tasis has been postulated, and direct evidence of EMT
has been demonstrated in a mouse mammary tumour
model [21]. A number of distinct changes occur during
the transition to a mesenchymal phenotype, most nota-
bly the down-regulation of epithelial markers such as E-
cadherin, and an upregulation of mesenchymal markers
including Snail, Slug, vimentin, Twist and fibronectin
[22]. In addition, a number of phenotypic changes occur
including loss of cell polarity and tight junction regula-
tion, accompanied by cytoskeletal changes [23,24] and
enhanced cell migration/invasion [25]. Id1 has pre-
viously been implicated with EMT both directly,
through suppression of E-cadherin and zonula occlu-
dins-1 (ZO-1), in human kidney cells [26] and indirectly,
through loss of Krueppel-like factor 17 (KLF17) in
breast cancer cells [27]. As such, we wished to clarify
whether the increase in cell migration following cyclin
D1 silencing was due to an Id1-dependent increase in
EMT markers.
In this study, we demonstrate that silencing Id1 pre-
vents the cyclin D1 mediated increase in MDA-MB-231
breast cancer cell migration. We have identified that an
increase in SNAI2 mRNA expression following cyclin
D1 silencing is abolished in cyclin D1/Id1 double
knock-down cells. A meta-analysis of primary breast
tumours revealed significant associations between
CCND1, ID1, CDH1 (E-cadherin) and recurrence-free
survival. CCND1 and ID1 gene expression was also cor-
related with EMT-associated genes including, VIM,
SNAI1, SNAI2, and TWIST1. Finally, the recently estab-
lished claudin-low subtype of breast cancer, which is
enriched in EMT markers, was found to have a four-
fold greater proportion of CCND1low/ID1high tumours
compared to other breast cancer subtypes.
Methods
Cell culture
The human breast cancer cell lines MDA-MB-231 and
ZR75-1 (ATCC, Int., Manassas, VA) were maintained in
RPMI 1640 medium supplemented with 10% fetal calf
serum (FCS), sodium pyruvate (1 mM) and 1 × PEST
(streptomycin 90 μg/ml, penicillin 90 IU/ml). Cells were
maintained in a humidified atmosphere of 5% CO2/95%
air at 37°C.
siRNA and vector transfections
7.5 × 105 cells were seeded in a 10 cm (47.16 cm2) cul-
ture dish with PEST-free serum-containing media (SM)
for 24 h. The media was subsequently removed and
PEST-free serum-free media (SFM) added along with 1
ml siRNA solution (OptiMEM, Gibco, Lipofectamine
2000, Invitrogen Life Technologies, Carlsbad, CA) giving
a final concentration of 40 nM oligonucleotides. 5 h
after transfection, SFM was replaced with SM and cells
were allowed to grow for 20 h before harvesting for
migration assay or western blot. ON-TARGETplus
SMARTpool siRNA targeting cyclin D1, Id1 or Slug
(Dharmacon RNA Technologies, Lafayette, CO) were
included as standard experimental protocol. A non-tar-
geting pool was used as negative control. For vector
experiments, cells were treated as above with the follow-
ing exceptions: seeding density was 11 × 105 cells in a
47.16 cm2 culture dish and 1.5 μg of Id1 vector pCMV-
SPORT6 or control vector pCMV6 was used (Invitrogen
Life Technologies, Carlsbad, CA).
Western blotting
Western blot was performed as previously described
[28] with the following antibodies: anti-cyclin D1 (1:500,
DCS-6, DAKO, Denmark), anti- Id1 (1:400, C-20, Santa
Cruz), and anti-Actin (1:1000, I-19, Santa Cruz, CA,
USA) Proteins were visualized with horseradish peroxi-
dase conjugated secondary antibodies using the
enhanced chemiluminescence detection system (Amer-
sham Pharmacia Biotech, Little Chalfont, UK).
Migration assays
Cell migration was routinely carried out in 8 μm-pore
polycarbonate membrane Transwell chambers with a
diameter of 6.5 mm (Corning, Inc. Corning, NY). The
membranes were incubated in 150 μl serum-free RPMI
1640 for an initial equilibrium period of 1 h. Cells were
resuspended in serum-free medium (1 × 106 cells/ml)
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and 100,000 cells were added to each migration cham-
ber. The chambers were placed into wells containing
600 μl 10% FCS medium and cells were allowed to
migrate for 4 h after siRNA or vector transfections.
Cells remaining in the chamber were removed with a
cotton swab and the migrated cells situated on the
lower side of membranes were fixed for 15 min in PBS
containing 4% paraformaldehyde. Membranes were cut
and mounted on glass slides for DAPI staining and
counted using a fluorescent microscope (cells in three
10X-magnification fields representing the composition
of the membrane were counted). Assays were performed
in triplicate with two migration membranes for every
treatment, and the total number of migrated cells was
used for graphical and statistical purposes.
qPCR and Chromatin immunoprecipitation assay (ChIP)
Total RNA was isolated using an RNeasy Plus Kit (Qia-
gen, West Sussex, UK). RNA was eluted and quantified
using a Nanodrop spectrometer (ThermoScientific, Lei-
cestershire, UK). The reverse transcription step was per-
formed using the TaqMan Reverse Transcription
Reagent Kit (Applied Biosystems, CA, USA) according
to manufacturer’s guidelines. TaqMan real time PCR
was designed using the Universal Probe Library (Roche
Diagnostics, West Sussex, UK). Primers and sequences
can be found in Additional File 1. RT-PCR was per-
formed with 5 ng template cDNA using Taqman Master
Mix (Applied Biosystems, CA, USA) and an ABI prism
7900 HT sequence detection system (Applied Biosys-
tems, CA, USA). ChIP assay was carried out using the
MAGnify™ Chromatin Immunoprecipitation System
(Invitrogen Life Technologies, Carlsbad, CA). 3 μg of
anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was
used to pull down cyclin D1, with subsequent detection
of Id1 using SimpleChIP™ Human Id1 Promoter Pri-
mers (Cell Signalling Technology, Danvers, MA) and
Mrg1 as positive control (Eurofins Laboratories Ltd.,
Manchester, UK). Promoter occupancy was calculated
based on the ratio of ChIP to input control.
Microarray analysis
Gene expression analysis of cyclin D1 silenced cells was
described previously [14]. All data is MIAME compliant
and raw data has been deposited at the NCBI Geo data-
base (Accession number GSE27260). A meta-analysis of
six Affymetrix gene expression datasets comprising a
total of 1107 primary human breast cancers was per-
formed as previously described [29]. Clinicopathological
features were retrieved from the original studies. The
follow up endpoints for the Chin et al., Pawitan et al.
and Sotoriou et al. datasets were recurrence-free survi-
val, whereas for Desmedt et al., Ivshina et al. and Wang
et al. datasets it was disease-free survival. The gene
expression datasets of Herschkowitz et al. [30] and Neve
et al. [31] were used to compare expression of ID1,
CCND1 and EMT-related genes across the breast cancer
subtypes, including claudin-low as determined by the
study and breast cell lines respectively.
Statistical methods
To examine the statistical significance of the differences
seen in the Boyden migration and qPCR a two-tailed
student’s t-test was employed, assuming unequal var-
iance. Unless noted otherwise, the standard error of the
mean is stated. Statistical analyses were performed using
SPSS software (version 17.0, SPSS, Chicago, IL, USA).
For examination of the statistical significance of associa-
tions between CCND1, ID1 and other categorical vari-
ables, Spearman’s rank-order correlation coefficient,
Kruskal-Wallis and Wilcoxon/Mann-Whitney tests were
used as indicated in figure legends. To study recur-
rence-free survival the Kaplan-Meier method was
employed and to compare recurrence-free survival
among different quartiles the log-rank test was used.
For claudin-low subtype comparison a Chi2 test was
employed.
Results
Cyclin D1 and Id1 in breast cancer cell migration
We have previously shown that cyclin D1 silencing
increases migration of the ER-negative MDA-MB-231
breast cancer cell line, an effect not observed when silen-
cing its binding partners CDK 4/6 (Lehn et al. 2010). ID1
was among the genes most significantly upregulated (Fig-
ure 1A, 1.40 ± 0.007 fold) in response to cyclin D1
knock-down (Figure 1A, 0.22 ± 0.017 fold) and was
unchanged following CDK 4/6 silencing. As a role for Id1
in breast cancer cell metastasis and aggressiveness has
previously been suggested [17], it was logical to examine
whether it was also responsible for the cyclin D1 induced
increase in cell migration. Western blotting confirmed an
increase in Id1 protein following cyclin D1 siRNA treat-
ment, and effective cyclin D1 and Id1 silencing (Figure
1B). In addition, neither Id1 silencing nor vector overex-
pression altered cyclin D1 protein levels after 24 h.
Boyden chamber migration assays accurately replicated
previous experimental results, with cyclin D1 siRNA
treatment of MDA-MB-231 cells increasing the total
number of migrated cells to 53.57 ± 3.5, compared to
control levels of 41.89 ± 3.0 (Figure 1C). Notably, Id1
siRNA decreased cell migration (31.13 ± 1.99), and addi-
tion of cyclin D1 siRNA was unable to significantly res-
cue this effect (46.00 ± 2.34). Overexpression of Id1
increased migration (67.13 ± 3.82 compared to control
of 36.33 ± 4.00) and similar effects were found when
treating cells with both Id1 vector and cyclin D1 siRNA
(67.24 ± 6.08). To discount the possibility that increased
Tobin et al. BMC Cancer 2011, 11:417
http://www.biomedcentral.com/1471-2407/11/417
Page 3 of 14
siRNA concentration may have a negative impact on
migration in the cyclin D1 and Id1 siRNA treated cells,
we assessed single and double concentrations of siRNA
in control cells and found no significant difference in
cell migration (data not shown). To determine if Id1
could be a transcriptional target of cyclin D1 in MDA-
MB-231 cells, we performed a ChIP assay, and demon-
strated that cyclin D1 occupancy in the Id1 promoter
was significantly higher (1.30% of input) in cyclin D1
pull-down than in a negative mouse IgG control, and
higher still than the positive control Mrg1 (Bienvenu et
al. 2010) (Figure 1D).
Figure 1 Effect of cyclin D1 and Id1 on breast cancer cell protein expression and migration. Actively cycling MDA-MB-231 and ZR75-1
cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in gene or protein
expression, and migration. Blots are representative, and plots are mean values from at least three independent experiments. Error bars represent
standard deviation. MDA-MB-231 cells: (A) Microarray analysis. Left panel: CCND1 gene expression, right panel: ID1 gene expression (B) Western
blot for cyclin d1, Id1 and Actin protein, (C) Cell migration as measured by Boyden chamber assay, dots indicate total number of migrated cells.
(D) ChIP assay for Id1 promoter region following cyclin D1 pull down. ZR75-1: (E) Western blot for cyclin d1 and Actin protein (F) Cell
migration- Boyden chamber assay. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student’s t-test.
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We next examined whether cyclin D1 silencing could
effect migration in an ER-positive breast cancer cell line
with similar cyclin D1 levels to MDA-MB-231 cells.
siRNA treatment against cyclin D1 reduced its protein
levels (Figure 1E) and also significantly increased migra-
tion (39.71 ± 5.04 compared to control of 20.14 ± 2.66,
Figure 1F) of ZR75-1 cells. However, given the extre-
mely low protein expression levels of Id1 in ZR75-1
cells, it is unlikely that the increase in migration is
mediated through Id1 in this cell line. In addition to the
interaction we have demonstrated between cyclin D1
and Id1, other regulators of Id1 have been previously
identified. TGF-beta [32], KLF17 [33] and Src [34] are
all known to interact and influence Id1 expression.
Thus, levels of Id1 protein in ZR75-1 cells may reflect
interactions with other transcriptional regulators. To
directly address this, we examined TGF-beta (a known
inducer of Id1 [32]) gene expression in a range of breast
cancer cell lines and noted high levels in MDA-MB-231
cells relative to ZR75-1 cells (Additional file 2). Impor-
tantly, none of the aforementioned transcripts were
altered in our expression array data in response to cyclin
D1 silencing and are hence unlikely to contribute to the
migratory effect we have observed.
Together, these data indicate that the increase in Id1
following cyclin D1 silencing in MDA-MB-231 cells is
responsible for their enhanced migratory capacity, but
that this does not appear to be the only mechanism by
which cyclin D1 can induce cell migration. Mounting
evidence has indicated the occurrence of an EMT-like
phenotype in migratory breast cancer cells [35,36].
Given this evidence we wished to determine whether
the Id1 induced increase in migration following cyclin
D1 silencing may be mediated through enhanced fea-
tures of EMT.
Cyclin D1 silencing in MDA-MB-231 cells increases EMT
gene expression in an Id1 dependent manner
Examination of EMT-related genes in the microarray
analysis of MDA-MB-231 cells showed significant
increases in SNAI2 (1.19 ± 0.03 fold), CDH11 (OB-Cad-
herin, 1.18 ± 0.03 fold), and TWIST1 (1.13 ± 0.05 fold),
following cyclin D1 silencing. A modest increase in
SNAI2 (1.06 ± 0.01 fold) expression was noted after
CDK4/6 silencing, but neither siRNA treatment had an
effect on SNAI1 or VIM expression (Figure 2A).
Using siRNA against cyclin D1 and Id1 we confirmed
significantly decreased levels of CCND1 by qPCR, and
found that Id1 siRNA had no significant impact on
CCND1 expression (Figure 2B) after 24 h. Increased ID1
levels (1.58 ± 0.09 fold) were noted following cyclin D1
silencing (Figure 2C) and the effect of Id1 siRNA on
ID1 expression was reduced when combined with cyclin
D1 siRNA (0.18 ± 0.01 vs. 0.28 ± 0.06 fold respectively,
P = 0.019). As noted in our microarray data, cyclin D1
silencing increased SNAI2 levels, a result validated by
qPCR analysis (1.41 ± 0.1 fold). This increase was
reversed when cyclin D1 was silenced in combination
with Id1 (0.73 ± 0.13 fold of control, Figure 2D). Id1
overexpression increased SNAI2 levels (1.34 ± 0.22 fold),
an effect greatly enhanced when cyclin D1 was also
silenced (2.39 ± 0.64 fold). Notably, silencing of cyclin
D1 was unable to increase MDA-MB-231 cell migration
when Slug was also silenced (Additional File 3). We also
observed an increase in SNAI2 expression following
cyclin D1 silencing (Figure 2E) in ZR75-1 cells (1.34 ±
0.05 fold, Figure 2F).
These results suggest a novel effect whereby cyclin D1
silencing enhances a mesenchymal phenotype in MDA-
MB-231 and ZR75-1 cells. In order to further validate
our hypothesis, we next examined gene expression data
from a large cohort of breast cancer patients.
CCND1 and ID1 expression are correlated to
clinicopathological parameters and predict recurrence risk
in breast cancer
To investigate the relationship between CCND1 and ID1
expression in primary breast tumours we used a pre-
viously published meta-analysis consisting of six groups
of tumours on Affymetrix arrays totaling 1 107 samples.
Due to the large number of patients and spread of gene
expression values we quartiled each gene, giving us the
following subgroups- 1 (low expression), 2 (low-med-
ium), 3 (medium-high) and 4 (high). Initial examination
of clinicopathological parameters revealed that ID1 was
negatively correlated to tumour grade (p < 0.001), and
size (p = 0.005). CCND1 expression was associated with
ER-positive breast cancers (p < 0.001), and lower histo-
logical grade (p = 0.002) (Table 1). Neither CCND1 nor
ID1 provided independent prognostic information in a
Cox multivariate analysis (data not shown).
Next, we determined how these quartiles related to
recurrence-free survival (RFS) in the combined datasets.
In all patients, and particularly in the subgroup of ER-
positive patients, high expression of CCND1 was asso-
ciated with the shortest RFS (p = 0.049 and p = 0.006,
respectively, Figure 3A, left and middle panels, log-rank
test). This effect was not observed in the ER-negative
subgroup (Figure 3A, right panel). Conversely, low ID1
expression was associated with the shortest RFS in all
patients (p < 0.001, Figure 3B, left panel), but not in the
ER-positive and negative subgroups (Figure 3B, middle
and right panels). The levels of EMT-related genes,
SNAI1 (Figure 3C), SNAI2 (Figure 3D), VIM or TWIST
(Additional File 4B and 4C) were not of significant prog-
nostic value. However, CDH1 (E-cadherin) significantly
predicted RFS in all and ER-positive patients (Additional
File 4A, left and middle panels).
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Low CCND1 and high ID1 expressing tumours show
increased EMT-related gene expression and predict risk of
recurrence in breast tumours
As our in vitro experiments indicated that CCND1low/
ID1high breast cancer cells exhibit increased invasion and
expression of the SNAI2 gene, and our survival analysis
indicated that low CCND1 and high ID1 expression can
predict RFS in breast cancer patients; we examined all
four combinations of CCND1low/high and ID1 low/high
gene expression in relation to well-characterised EMT
genes in all patients of the same tumour material. The
highest expression of SNAI2, TWIST1, VIM and lowest
expression of CDH1 was found in the CCND1low/ID1high
subgroup of tumours (Figure 4A, yellow bars). Further
weight was added to this analysis when examining the
CCND1low/high/ID1low subgroups of tumours (Figure 4A,
red and blue bars, respectively). These tumours encom-
pass the lowest expression of SNAI2, TWIST1, VIM and
highest expression of CDH1. This suggests, as our
MDA-MB-231 in vitro experiments demonstrated, that
cyclin D1 is unable to influence the induction of EMT
in the absence of Id1.
Figure 2 Effect of cyclin d1 and Id1 on EMT markers. MDA-MB-231 cells were monitored 20 h post-transfection with the indicated siRNA
(cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in EMT-related gene expression by microarray analysis. Additionally, MDA-MB-231 and ZR75-1
gene expression was examined by qPCR assay. Plots are mean values from at least three independent experiments Error bars represent standard
deviation. (A) Microarray analysis of SNAI1, SNAI2, CDH11, TWIST1 and VIM gene expression. (B-D) CCND1, ID1 and SNAI2 in MDA-MB-231 cells. (E,
F) qPCR analysis of CCND1 and SNAI2 in ZR75-1 cells. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student’s t-test.
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To gain further insight into the relationship between
cyclin D1 and Id1 we examined the CCND1low/ID1high
subgroups with regards to RFS in all, ER-positive, and
negative patients. No statistical significance was found
when examining all (data not shown) or ER-negative
patients however, high ID1 expression was associated
with the shortest RFS (Figure 4B, left and right panels)
in CCND1low ER-positive tumours. In addition, both low
and high CCND1 expression was associated with the
shortest RFS in ID1high ER-positive tumours with no sta-
tistical significance observed in all (data not shown) or
ER-negative patients (Figure 4C, left and right panels).
Low CCND1 and high ID1 expression is dominant in the
EMT-related basal B breast cancer cell lines and claudin-
low subtype of tumours
A number of studies [31,37-39] have consistently split
breast cancer cell lines into three groups based on their
gene expression profiles; luminal, basal (or basal A) and
mesenchymal/basal B/claudin-low subtypes. A greater
proportion of the mesenchymal/basal B/claudin-low cell
lines have low CCND1 and high ID1 expression than
luminal (including ZR75-1) or basal A subtypes (Figure
5A-C) in the Neve et al. dataset (profiles for the same
cell lines are highly correlated across several indepen-
dent studies, data not shown) and have increased
expression of EMT markers (SNAI1, SNAI2, TWIST1,
VIM), along with low CDH1. Although ZR75-1 cells
have similar levels of CCND1, they are of luminal sub-
type and display high expression of CDH1 (Figure 5A).
This demonstrates the distinct difference between these
cells lines, which may explain why Id1 appears unneces-
sary for enhanced EMT features in ZR75-1 cells follow-
ing cyclin D1 silencing.
Recent studies have identified a ‘claudin-low’ subtype
of breast cancer amongst human tumours through gene
transcriptional profiling [30,40,41]. Tumours of the clau-
din-low subtype putatively contain tumour initiating
cells (TIC), display high expression of EMT markers,
and are believed to be the closest representation of an
EMT phenotype in breast cancer [42]. This subtype dis-
played the highest proportion of CCND1low/ID1high
Table 1 Distribution of CCND1 and ID1 gene expression according to clinico- pathological parameters in breast cancer
patients
CCND1 ID1
Variable 1
N = 277
2
N = 276
3
N = 277
4
N = 277
1
N = 277
2
N = 276
3
N = 277
4
N = 277
ERa positive (%)
P- value
(R-value)
< 0.001†
(0.306)
0.529†
(0.021)
< 10 118 49 44 28 61 66 52 60
≥ 10 117 177 195 211 172 170 182 176
Missing cases: 168
NHG
P- value
(R-value)
0.002
(-0.098)
< 0.001
(-0.199)
I 27 48 60 32 22 41 44 60
II 72 79 86 93 77 78 87 88
III 96 73 53 65 90 84 62 51
Missing cases: 323
Lymph node status
P- value
(R-value)
0.360†
(0.030)
0.078†
(-0.058)
N = 0 192 198 200 190 190 190 197 203
N > 0 41 30 39 47 43 48 33 33
Missing cases: 170
Tumour size, mm
P- value
(R-value)
0.415†
(-0.032)
0.005†
(-0.109)
≤ 20 71 90 97 80 63 91 89 95
> 20 90 75 73 86 95 83 69 77
Missing cases: 445
* Correlations were calculated using Spearman’s r unless otherwise specified
† Wilcoxon/Mann-Whitney test (two-sided)
ER, Oestrogen receptor; NHG, Nottingham Histologic Grade.
Tobin et al. BMC Cancer 2011, 11:417
http://www.biomedcentral.com/1471-2407/11/417
Page 7 of 14
expressing tumours (Figure 5D-F). These data are con-
sistent with our observation that CCND1low/ID1high
tumours belong to a subgroup of breast tumours with
distinct expression pattern of CCND1, ID1 and EMT
related genes.
Discussion
In this study we demonstrate that the increase in MDA-
MB-231 cell migration following cyclin D1 silencing is
dependent on the upregulation of Id1. Previous studies
have found both similarities and differences to our
experimental model. Caldon et al. showed an increase
in Id1 protein in mouse mammary epithelial cells iso-
lated from cyclin D1-/- mice compared to wild type, in
line with our observations. Moreover, they also estab-
lished the inability of Id1 to promote proliferation of
mammary acini in the absence of cyclin D1 [43]. Swar-
brick et al. revealed a decrease in cyclin D1 expression
48 h after Id1 silencing in MCF7 cells [44], and others
report the same effect in both MCF7 and MDA-MB-231
cells [45]. We did not observe this decrease in cyclin D1
protein expression in MDA-MB-231 cells after 24 h in
our study. However, qPCR analysis showed a similar
decrease in cyclin D1 mRNA levels which may become
Figure 3 Correlation of CCND1, ID1, SNAI1 and SNAI2 expression to recurrence free survival. Expression of our genes of interest in relation
to recurrence-free survival was examined in a breast cancer database containing 1,107 tumours from Sims et al. (2008). Gene expression intensity
was quartiled as 1-low, 2- medium low, 3- medium high and 4- high, and assessed in all patients, ER-positive and ER-negative patients,
respectively (A) CCND1 quartiles (B) ID1 quartiles (C) SNAI1 quartiles (D) SNAI2 quartiles. P-value is based on log-rank test.
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more apparent on the protein level after 48 h. Bienvenu
et al. demonstrated binding of cyclin D1 to the promo-
ter region of ID1 in mouse retinal cells, and when com-
paring wildtype to CCND1-/- mice found an 8-fold
enrichment of ID1. We have also observed occupancy of
the Id1 promoter region by cyclin D1 in MDA-MB-231
cells, where it may repress Id1 expression. These data
demonstrate the complex relationship between cyclin
D1 and Id1. It is important to note that here we are
only proposing this mechanism in MDA-MB-231 cells
and in a distinct subset of representative breast tumours.
We observed this complexity during the course of our
work, where despite an increase in ZR75-1 migration
following cyclin D1 silencing, Id1 protein levels were so
low as to not substantially contribute to this effect. We
postulate that in ZR75-1 cells other known transcription
regulators of Id1 such as TGF-beta may be responsible
for repressing expression of the protein. Importantly,
TGF-beta and other known Id1 regulators (KLF17, Src)
were unchanged in our MDA-MB-231 microarray fol-
lowing cyclin D1 silencing, indicating they do not con-
tribute to the upregulation of Id1 or migration in our
analysis.
It is pertinent to highlight that the increase in migra-
tion we have observed is occurring in an already highly
invasive, mesenchymal-like cell line. This may account
for a lessened migratory response to cyclin D1 silencing.
Further evidence of this concept is shown in the more
epithelial-like, less typically invasive ZR75-1 cells, where
the increase in cell migration is more pronounced (1.89
Figure 4 EMT-related gene expression intensity and recurrence free survival in CCND1/ID1 high and low tumours. A breast cancer
database was employed to examine (A) Mean-centered average expression of EMT-related genes of interest in CCND1/ID1 subgroups, and (B, C)
Recurrence-free survival of ER-positive and negative patients in CCND1/ID1 subgroups. P-value is based on log-rank test.
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fold vs. 1.3 fold in MDA-MB-231) following cyclin D1
knock-down. In addition, cyclin D1 is known to be
expressed at variable levels across cell lines and subtypes
of breast cancer thus, silencing of cyclin D1 is unlikely
to increase migration uniformly in all cell types.
A common feature in our MDA-MB-231 and ZR75-1
cells was an increase in SNAI2 expression 24 h after
cyclin D1 knock-down, which coincided with an
increase in cell migration. In MDA-MB-231 cells, silen-
cing of Id1 reversed this and SNAI2 expression was
decreased, as was cell migration. Moreover, silencing
of Slug- the SNAI2 protein, significantly decreased
MDA-MB-231 migration, and cyclin D1 silencing was
unable to rescue this effect. These migratory observa-
tions for SNAI2 are in line with previous experimental
data, indicating that Slug expression induces a migra-
tory phenotype and can represses E-cadherin, inducing
an EMT in epithelial cells [46]. Moreover, siRNA
against Slug decreases MDA-MB-231 cell migration
[47], and Slug and Snail are overexpressed invasive
Figure 5 Gene expression of Cyclin d1/Id1 and EMT markers in breast cancer cell lines and claudin-low tumours. Expression of EMT and
related genes from the Neve et al cell line (A-C) and Herschkowitz et al. claudin-low (D-F) studies. (A and D) Heatmaps showing relative
expression of genes of interest, Red = high, Green = low. (B and E) Scatterplots showing the relationship between breast cancer subgroups and
CCND1/ID1 expression (C and F) Proportion of CCND1-low/ID1-high cell lines and tumours in breast cancer subgroups. ***P ≥ 0.001, Chi2 test.
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ductal carcinoma [48]- a form of breast cancer hall-
marked by cell migration. In our experimental model,
Slug would appear a likely candidate mediating the
observed migratory effects, however it is entirely plau-
sible that it does so in conjunction with other EMT
factors. We also found statistically significant changes
in TWIST1 and CDH11 (the positive EMT-regulator
also known as OB-cadherin) following cyclin D1 silen-
cing, both of which have been implicated with
enhanced cell motility [49,50]. The changes in our
EMT markers are in the order of 1.13 to 1.19 fold of
control by expression array analysis (Figure 2A). We
note that these figures are more meaningful when
taken in the context of the most increased gene in our
expression array, which was only upregulated 1.8 fold
[14]. As may be expected from treatment with siRNA,
many more genes were downregulated in the array
analysis than upregulated, again highlighting the
importance of the increases in our mesenchymal mar-
kers. It is likely that all of these factors work in con-
cert to promote a migratory and EMT-like phenotype,
and that small gains in expression of a number of
EMT genes can contribute to a greater overall effect.
The relationship between cyclin D1 expression and
patient outcome remains a controversial area, with stu-
dies reporting both positive and negative associations.
CCND1 gene amplification has been related to poor dis-
ease outcome in ER-positive patients [51,52], but others
correlate cyclin D1 protein expression with both better
[53,54] and worse [55] prognosis. It has been proposed
that subgroup analysis with small numbers of patients
[56] and splice variants of the gene have contributed to
these contrasting results. In agreement with others [57],
we found an association between high CCND1 expres-
sion and poor prognosis (Figure 3A). However, when
examining ID1 high tumours, both the highest and low-
est expression quartiles of CCND1 were correlated to
reduced RFS/DFS but only in the ER-positive subgroup
(Figure 4C). A similar trend was noted for ID1, where in
all patients low expression of the gene was associated
with a shortest RFS (Figure 3B), but in the CCND1 low
ER-positive subgroup of tumours, a positive correlation
was found (Figure 4B).
Whilst this may appear contrasting to our in vitro
data, we reason that cyclin D1 low, ER-positive tumours
best represent our cell line model. We chose two cell
lines (MDA-MB-231 and ZR75-1) based on their high
expression of cyclin D1 (regardless of oestrogen receptor
status). We then reduced these high levels using siRNA
and noted an increase in cell migration and EMT mar-
kers. As ER-negative tumours are consistently cyclin D1
low, these are less representative our in vitro experi-
ments. ER-positive tumours however are typically cyclin
D1 high, thus by choosing tumours that are cyclin D1
low in this subgroup, we are more correctly mimicking
our in vitro setting, where expression of cyclin D1 may
have been lost. This yields the interesting observation
that ER-positive tumours with low cyclin D1 appear to
behave similarly to ER-negative tumours with regards to
their relationship to EMT markers and the claudin-low
subtype. Thus, should ER-positive tumours that have
lost expression of cyclin D1 be considered more ER-
negative-like? Whilst the answer to this question is far
beyond the scope of this study, what is clear is that the
effect we are observing is centred on loss of cyclin D1
and not on the oestrogen receptor status of our testing
material.
Interestingly, the CCND1low/ID1high and CCND1high/
ID1high tumours both displayed increased expression of
EMT-related genes (Figure 4A, yellow and green bars
respectively). This suggests that in the context of these
subgroups, ID1 is vital for increased EMT gene expres-
sion and when CCND1 is low it enhances the EMT
phenotype.
We did not observe any meaningful impact of EMT
genes in individual Kaplin-meier analysis on patient sur-
vival in our dataset. There has been an explosion of
EMT related data in recent years in the breast cancer
field. Central to many of these publications has been the
ability of EMT to putatively enhance stem cell-related
features and promote the metastatic process [58,59]. Of
particular note, the idea of cells that have undergone
EMT residing at the leading edge of an invasive tumour
and promoting metastasis at the tumour- stroma inter-
face has garnered much attention [60]. This hypothesis
may be one explanation as to why EMT markers such
as SNAI1, SNAI2, TWIST1 and VIM do not show any
prognostic significance in our model- if the cells that
have undergone EMT reside at the leading edge of the
tumour, strong expression of their genes could easily be
lost amongst the entirety of the tumour body. In these
circumstances, any strong links to prognosis would also
be diluted.
A second, more straightforward explanation as to why
we have not observed prognostic significance of EMT-
related genes centers upon a keystone principal. Upre-
gulation of one EMT gene, e.g. SNAI1, is not enough to
induce a transition to mesenchymal phenotype. This is
supported by the board range of expression values of
EMT genes across all breast cancer tumours and sub-
types in our study (Figure 5D). Induction of EMT
requires a reduction in CDH1 expression and upregula-
tion of the potent SNAI1, SNAI2 and TWIST1 genes
(amongst others). In order to examine the effect of
EMT in our cohort, we would have to combine all
tumours with these gene properties- giving us a ‘clau-
din-low’ subgroup. Unfortunately, we have too few cases
in our claudin-low dataset to give any relevant
Tobin et al. BMC Cancer 2011, 11:417
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prognostic information. In order to explore this further
a cohort consisting of a large representation of claudin-
low tumours, preferably with micro-dissection of the
tumour-stroma interface would be required.
Much like CCND1, some controversy surrounds
expression patterns of ID1, and despite numerous links
to invasion and migration in breast cancer [43,44] some
groups report an absence of the protein in the normal
mammary gland [61]. Perk et al. assessed Id1 protein
expression in mammary carcinomas [62] and found
nuclear expression of Id1 in a rare subtype of breast
cancer, metaplastic mammary tumours. Metaplastic can-
cers have a unique genetic profile that is notably, most
closely related to the claudin-low subtype of breast can-
cer [41,63,64] and are very poorly differentiated. Given
the poor outcome associated with metaplastic cancer, it
may indicate why high ID1 expression in CCND1 low
tumours gave the shortest RFS.
Adding further weight to our analysis, we found the
greatest proportion of CCND1low/ID1high cell lines and
tumours in the claudin-low subgroup, which have a
poor prognosis [65], associations with EMT and che-
motherapy resistance [66] and has stem-cell tumour
initiating features [42]. A number of these properties are
reflected in both the cell lines and patient material used
within this study, potentially indicating a central role for
cyclin D1 and Id1 in this subgroup.
Conclusions
The increase in MDA-MB-231 migration we have
observed following cyclin D1 silencing is dependent on
an upregulation of Id1 and induction of a more
mesenchymal phenotype. Patients with CCND1low/
ID1high tumours have a shorter RFS and we have shown
a link between CCND1low/ID1high tumours and the clau-
din-low subgroup of breast cancer.
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